Zurich — GlaxoSmithKline said on Tuesday it will buy Novartis’s 36.5% stake in their consumer healthcare joint venture for $13bn in cash, and will also begin a strategic review of some other businesses. GSK last week quit the race to buy Pfizer’s consumer healthcare business, endangering an auction the US drugmaker hoped would bring in as much as $20bn. Instead it will take full control of the Novartis venture formed in 2015 whose products include Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches used by smokers who want to quit their habit. "The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world’s leading consumer healthcare businesses," CEO Emma Walmsley said in a statement. The deal would boost adjusted earnings and cash flows, helping to accelerate efforts to improve performance, she said. "Most importantly it also removes uncertainty a...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.